MNPR-101-radioimmunotherapeutic

N/A

Report date: 2025/10/30 15:24:37

Base Information

Drug NameMNPR-101-radioimmunotherapeutic
Drug Alias NameMNPR 101 radioimmunotherapeuticMNPR-101-radioimmunotherapeuticMNPR-101-PCTA-225ACMNPR-101-PCTA-225-ACMNPR-101-PCTA-AC-225 +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agent +[4] 
Mechanisms of ActionIonising radiation emittersAnti-Urokinase plasminogen activator surface receptor
TargetsUrokinase plasminogen activator surface receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMonopar Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMonopar Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A